Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04440007 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19
A Phase 2 study, sponsored by Sorrento Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT04440007 is a Phase 2 study that has completed, run by Sorrento Therapeutics. The registered enrollment target is 96 participants.
The verdict
NCT04440007, a Phase 2 study, has completed, sponsored by Sorrento Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
Study to assess the safety and efficacy of STI-5656 (Abivertinib Maleate) plus SOC versus SOC in subjects hospitalized with COVID-19
Interventions
- OTHER Standard of Care
- DRUG Abivertinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2020-10-09 |
| Est. Completion | 2021-08-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04440007
The ClinicalTrials.gov registry entry for NCT04440007 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sorrento Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT04440007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04440007 about?
NCT04440007 is a clinical study titled "Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19". Study to assess the safety and efficacy of STI-5656 (Abivertinib Maleate) plus SOC versus SOC in subjects hospitalized with COVID-19
What is the current status of trial NCT04440007?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2020-10-09. Estimated completion is 2021-08-23.
What interventions are being tested in trial NCT04440007?
The interventions under investigation include: Standard of Care (OTHER), Abivertinib (DRUG).
Who is sponsoring clinical trial NCT04440007?
This trial is sponsored by Sorrento Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.